Two-year clinical outcomes after large coronary stent (4.0 mm) placement: comparison of bare-metal stent versus drug-eluting stent

Clin Cardiol. 2010 Oct;33(10):620-625. doi: 10.1002/clc.20781.

Abstract

Background: The absolute benefit of drug-eluting stents (DES) in low-risk patients and lesions is not well established.

Hypothesis: The long term clinical outcomes after percutaneous coronary intervention in a single coronary artery disease may not be affected by the type of stent.

Methods: This study assessed and compared 2-year clinical outcomes of 304 consecutive patients (147 BMS patients and 157 DES patients) treated with a single coronary stent (4.0 mm) for single de novo large coronary artery disease in 3 referral cardiac centers. The primary outcome was a composite of major adverse cardiac events at 2 years after the index procedure.

Results: The reference vessel diameter was similar in both groups (3.92 ± 0.29 mm in BMS vs 3.95 ± 0.24 mm in DES, P = 0.50). Late loss was larger in the BMS group (1.04 ± 0.83 mm vs 0.73 ± 0.91 mm in DES, P = 0.03). The incidence of major adverse cardiac events at the 2-year clinical follow-up was very low, 24 of 304 patients (7.9%), regardless of stent type deployed (7.5% in BMS vs 8.3% in DES, P = 0.83). The rate of target vessel revascularization was also similar in both groups (4.8% in BMS vs 5.7% in DES, P = 0.80).

Conclusions: Two-year clinical outcomes after PCI with a single large coronary stent (4.0 mm) were excellent. The clinical outcomes were not affected by the type of stent used.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Coronary Angiography
  • Coronary Stenosis / diagnostic imaging
  • Coronary Stenosis / surgery*
  • Drug-Eluting Stents*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Paclitaxel / pharmacology
  • Postoperative Period
  • Prosthesis Design
  • Retrospective Studies
  • Severity of Illness Index
  • Sirolimus / analogs & derivatives
  • Sirolimus / pharmacology
  • Time Factors
  • Treatment Outcome
  • Tubulin Modulators / pharmacology

Substances

  • Tubulin Modulators
  • zotarolimus
  • Paclitaxel
  • Sirolimus